NCT04034095 2025-12-15
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
Completed
Clinical Trials
16 trialsNCT03072238 2025-06-06
IPATential150
Hoffmann-La Roche
Phase 3 Completed
NCT03834519 2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02288247 2025-04-08
PRESIDE
Astellas Pharma Inc
Phase 3 Completed
NCT02043678 2025-02-19
ERA 223
Bayer
Phase 3 Completed
NCT01685268 2024-08-02
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01972217 2023-11-14
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
AstraZeneca
Phase 2 Completed
NCT01995513 2023-09-18
PLATO
Pfizer
Phase 4 Completed
NCT01685983 2019-03-15
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed
NCT01756638 2017-10-23
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed
NCT01308580 2017-04-17
PROSELICA
Sanofi
Phase 3 Completed
NCT02441894 2017-01-24
PEGAZUS
Sanofi
Phase 4 Completed
NCT00498797 2016-10-07
E3-Hormone Refractory Prostrate Cancer Taxotere Combination
Sanofi
Phase 2 Completed
NCT00519285 2016-07-22
VENICE
Sanofi
Phase 3 Completed
NCT00473746 2014-04-29
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT00554918 2013-08-07
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed